The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

SpringWorks Therapeutics, Inc. Selected Balance Sheet Data(Unaudited) September 30, 2023 December 31, 2022 (in thousands) Cash, cash equivalents and marketable securities $ 422,419 $ 597,006 ...

--SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of ...

SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...

Get the latest news on SpringWorks Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SWTX performance ...

SpringWorks is committed to improving our understanding of desmoid tumors. There’s a significant need for more education and we are working with urgency and tenacity to help improve the outcomes for ...

Current Position of SpringWorks Therapeutics Trading volume stands at 363,208, with SWTX's price down by -2.76%, positioned at $58.27. RSI indicators show the stock to be may be overbought.

SpringWorks is using Nirogacestat, while AbbVie provides ABBV-383. It is believed that Nirogacestat provides a boost for BCMA therapies like ABBV-383. This isn't the first partnership for SpringWorks.

About SpringWorks Therapeutics At SpringWorks, a clinical-stage biopharmaceutical company, we are driven to develop life-changing medicines for patients with severe rare diseases and cancer.

STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for ...